NeuShen Therapeutics, described as a Shanghai and Boston biotech led by a veteran transpacific drug developer, raised more than $80 million in a Series B to advance three clinical-stage brain-health drugs. The financing is intended to support continued development across neurological programs. The funding underscores investor appetite for CNS pipelines where differentiation often depends on clinical design and trial execution. By funding multiple programs simultaneously, NeuShen is betting on parallel progress to de-risk development timelines. The deal also reflects continued capital flows into late-stage innovation for brain and behavior indications, where operational scale and biomarker strategy can be decisive.